Coherus Oncology, Inc. current report, 14 June 2023

Full document

Business Context and Reporting Period

This Form 8-K was filed by Coherus BioSciences, Inc. on June 15, 2023, reporting events occurring between June 6 and June 14, 2023. The filing addresses a legal dispute with AbbVie Inc. regarding the Company's settlement and license agreement for the commercialization of YUSIMRYTM in the United States, scheduled to commence on July 1, 2023.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material legal event rather than financial performance data.

Material Changes and Events

  • Dispute Initiation: On June 6, 2023, AbbVie notified Coherus of an alleged breach of their license agreement due to Coherus's June 1, 2023 announcement of a pricing agreement with Mark Cuban Cost Plus Drug Company (CPD).
  • Legal Action: Coherus denied the allegation on June 11, 2023. To secure access to the license for the upcoming July launch, Coherus filed a motion for a temporary restraining order (TRO) in the Delaware Court of Chancery on June 13, 2023. AbbVie simultaneously filed a motion for a preliminary injunction.
  • Resolution: On June 14, 2023, the parties entered into a stipulation resolving the TRO motion. AbbVie agreed not to terminate the agreement based on the June 6 notice and agreed to provide a new notice of breach and a cure period before any future termination.

Outlook, Risks, and Management Commentary

The primary risk identified was the potential termination of the AbbVie Agreement, which would have jeopardized the planned July 2023 launch of YUSIMRYTM. The stipulation reached on June 14 mitigates this immediate risk by ensuring the Company retains access to the license while the underlying dispute regarding the CPD pricing agreement is addressed. No specific financial guidance or forward-looking projections were included in this filing.

Investor Verification Checklist

  • Verify the terms of the stipulation regarding the cure period for alleged breaches.
  • Monitor the status of the underlying dispute concerning the CPD pricing agreement.
  • Confirm the July 1, 2023 launch timeline for YUSIMRYTM remains on schedule.
  • Review future filings for any new notices of breach from AbbVie.